-Reuters
Jefferies Initiates Coverage On CinCor Pharma with Buy Rating, Announces Price Target of $30
Jefferies analyst Dennis Ding initiates coverage on CinCor Pharma (NASDAQ:CINC) with a Buy rating and announces Price Target of $30.
Broadcom CEO Says With Expected ‘Exponential Demand’ From Hyperscalers, Forecast That Ethernet Switch Shipments Used In AI Could Grow To Over $800M In 2023
-Reuters
Related Posts
Nektar Announces Poster Presentations At The 64th American Society Of Hematology Annual Meeting
-- Unveils Trial Design for Nektar Phase 2/3 Study Combining NKTR-255 with CAR-T Therapies --
-- Presents First Data for NKTR-255 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple
Tutor Perini Q3 EPS $0.30 Misses $0.63 Estimate, Sales $1.18B Miss $1.33B Estimate
Tutor Perini (NYSE:TPC) reported quarterly earnings of $0.30 per share which missed the analyst consensus estimate of $0.63 by 52.38 percent. This is a 58.33 percent decrease over earnings of $0.72 per share from the
Manitex International Q2 EPS $0.11 Beats $0.02 Estimate, Sales $60.05M Beat $51.65M Estimate
Manitex International (NASDAQ:MNTX) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.02 by 450 percent. This is a 237.5 percent increase over losses of $(0.08) per share from